• Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=811

    Chinese tea brand "CHALI" successfully completed a new round of financing of several hundred million RMB. The funding was led by GGV Capital, with continued investment from B-round lead investor Country Garden Venture Capital, as well as participation fro

  • Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=812

    closing of a RMB 200 million Series B+ financing round. The funding was led by Qiming Venture Partners, with participation from BioVenture, C&D Emerging Industry Investment, and existing shareholder Sino-Ocean Capital. CEC Capital Group acted as the e

  • Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=813

    On June 1, 2021, Stemirna announced the closing of a $200 million round of financing, led by China Merchants Capital, HongShan, King Lin investment, and WuXi AppTec, with participation from OrbiMed Advisors, Advantech Capital, Zhejiang Guotong Investment,

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=814

    HYGEIA (6078.HK) announced the acquisition of a 98% stake in Suzhou Yongding Hospital for a transaction size of RMB 1.7 billion. With this acquisition, Ascendent Capital, the controlling shareholder of Yongding Hospital, has completely divested its owners

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=815

    Genome Grecision, a rare domestic provider specializing in comprehensive molecular diagnostics solutions for hematological diseases, announced the closing of roughly RMB 200 million in Series C financing. This round of financing was jointly led by Sunland

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=566

    Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announces the completion of over 400M CNY Series-B financing round. The financing was led by GL Ventures, the venture capital unit of Hillhouse Capital, with participation from Cormorant Asset Management, VMS Group, and Heda Biopharmaceutical Venture Capital. The Series B financing round was also supported by existing investors, Sherpa Healthcare Partners and Oriental Fortune Capital. CEC Capital Group acted as the exclusive financial advisor in the transaction.

  • Cancel
    Date：2021-04

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=561

    Arrail Group (“Arrail” or the “Company), a leading dental service provider in China, announced that it has closed its Series E financing, with a transaction value of nearly $200M. The transaction was led by Temasek, with participation from OrbiMed, Ward Ferry, Hina Group, Industrial Bank and Mirae Asset. CEC Capital Group was the exclusive financial advisor on this transaction, and is proud to have advised Arrail since its Series A round of financing.

  • Cancel
    Date：2021-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=818

    The innovative artificial joint company b-ONE successfully closed a B-round financing of several hundred of million RMB, marking it the the largest RMB financing in the domestic orthopedic joint sector in recent years. The funding was led by Huatai Zijin